Diese Präsentation wurde erfolgreich gemeldet.
Die SlideShare-Präsentation wird heruntergeladen. ×
Anzeige
Anzeige
Anzeige
Anzeige
Anzeige
Anzeige
Anzeige
Anzeige
Anzeige
Anzeige
Anzeige
Anzeige
Wird geladen in …3
×

Hier ansehen

1 von 17 Anzeige
Anzeige

Weitere Verwandte Inhalte

Diashows für Sie (20)

Ähnlich wie RABBIT 2 (20)

Anzeige

Aktuellste (20)

Anzeige

RABBIT 2

  1. 1. RABBIT 2 SUMMARIZED BY DR. MARIA MORKOS Umpierrez, et al. “Randomized study of basal bolus insulin therapy in the inpatient management of patients with Type 2 Diabetes (RABBIT 2 Trial).” Diabetes Care. 2007. 30:2181-2186.
  2. 2. Randomized Study of Basal Bolus Insulin Therapy in the Inpatient Management of Patients with Type 2 Diabetes (RABBIT 2) Summarized by: Maria Morkos, MD; Laxmi Suthar, MD
  3. 3. BACKGROUND  Hyperglycemia is associated with increased clinical complications such as prolonged hospital stay, risk of infection, and mortality  Prior research had looked at hyperglycemia in critically ill/ICU patients  Hyperglycemia has been frequently overlooked on the inpatient medicine and surgery services  Many reports have shown that most hospitalized patients are treated with SSI; less than half have basal insulin prescribed  Few clinical trials have focused on the optimal management of inpatient hyperglycemia in the noncritical setting
  4. 4. CLINICAL QUESTION How does a basal/bolus insulin regimen compare to sliding scale regular insulin in patients with type 2 diabetes in terms of efficacy and safety?
  5. 5. DESIGN  Trial Design: randomized, open label, multicenter (Emory University and University of Miami)  N=130  Glargine daily + glulisine TID (n=65)  Adjustable regular SSI (n=65)  Primary outcome: mean daily blood glucose  Secondary outcomes: hypoglycemia, length of stay, mortality
  6. 6. POPULATION Inclusion Criteria  Insulin naïve pts with type 2 diabetes for at least 3 months  Admission blood glucose 140-180 mg/dL  Admitted to inpatient medical unit Exclusion Criteria  New onset diabetes  Prior insulin use  Steroid use  DKA/HHS  ICU admission  Liver disease  Cr > 3mg/dL  Impaired mental status  Pregnancy
  7. 7. INTERVENTIONS  Patients randomly assigned to either:  Glargine daily + glulisine TID, or  Regular sliding scale insulin  Unblinded study  Power calculations not specified (and unclear how pts were screened and excluded)
  8. 8. RESULTS  Mean daily glucose was 27 mg/dL lower in the basal-bolus group (p < .01)  BG target of <140 mg/dL was achieved in 66% of patients in basal-bolus group  Same BG target of <140 was achieved in 38% of patients in SSI group  No significant difference in length of hospital stay between the two groups  3% hypoglycemia (BG< 60) in both groups  One patient death in basal-bolus group
  9. 9. CRITICISMS/LIMITATIONS/FUNDING  Not powered to detect a mortality difference between treatment groups  Study was unblinded; sample size small with unspecified power calculations  Excluded pts with known history of diabetes, which make up a large percentage of hospitalized pts  Excluded pts treated with insulin and corticosteroids b/c they were considered at higher risk of severe hyperglycemia if treated with SSI  Other insulin regimens were not investigated  Funding: manufacturer of Lantus (Sanofi-Aventis)
  10. 10. BOTTOM LINE Treatment with basal-bolus insulin resulted in improved glycemic control compared to treating with only SSI. - No major difference in episodes of hypoglycemia - No major difference in length of hospital stay
  11. 11. DISCUSSION QUESTIONS  What insulin regimen in the inpatient setting can provide improved glycemic control, based on the RABBIT 2 trial?  What BG value did the study target for medicine inpatients?  There were two clinical outcomes that resulted the same for both arms of the trial; what were they?
  12. 12. DISCUSSION ANSWERS  What insulin regimen in the inpatient setting can provide improved glycemic control, based on the RABBIT 2 trial?  ANSWER: Long acting Lantus with mealtime insulin (in this trial, they tested glulisine=regular insulin)  What BG value did the study target for medicine inpatients?  ANSWER: BG <140  There were two clinical outcomes that were the same for both arms of the trial; what were they?  ANSWER: Episodes of hypoglycemia and length of stay
  13. 13. BOARD-LIKE QUESTION 25 yo F with PMH sig for only T1DM is evaluated for new glycemic fluctuations. Her A1c levels since dx 3 years ago ranged from 6.2% to 7.3%, with the most recent being 7.3%. She recently started a new high demand job but continues to eat a carb consistent diet that does not change from day to day; she also continues to exercise daily. Her insulin regimen is glargine once daily and insulin lispro TID. VS, PE wnl. eGFR, Cr, and urine albumin:Cr ratio all wnl. Her breakfast glucose values are 101-126; lunch BG 92-190; dinner BG 102-204; bedtime BG 72-210. QUESTION Which of the following is most likely causing the fluctuating glycemic control? A. Antibodies to exogenous insulin B. Gastroparesis C. Inadequate insulin doses D. Inappropriate insulin timing
  14. 14. BOARD-LIKE QUESTION QUESTION Which of the following is most likely causing the fluctuating glycemic control? A. Antibodies to exogenous insulin B. Gastroparesis C. Inadequate insulin doses D. Inappropriate insulin timing Educational Objective: Evaluate timing of prandial insulin in a pt with DM Key Point: - Meal coverage with insulin should mimic the physiologic pattern seen with endogenous insulin secreted from the pancreatic beta cells - Insulin administration should therefore be prior to or at the time of meal consumption
  15. 15. BOARD-LIKE QUESTION A 57-year-old man is admitted to the hospital for evaluation of substernal chest pain. His medical history is significant for type 2 diabetes mellitus, coronary artery disease, hypertension, and hyperlipidemia. He manages his diabetes as an outpatient with diet, exercise, and metformin. His other medications are aspirin, metoprolol, atorvastatin, and sublingual nitroglycerin as needed. His inpatient plasma glucose values are 170 to 210 mg/dL (9.4-11.6 mmol/L). Results of all other laboratory studies are normal. (Adapted from MKSAP 17) QUESTION Which of the following is the most appropriate treatment for this patient's diabetes while hospitalized? A. Basal and prandial insulin B. Glipizide C. Metformin D. Sliding-scale insulin
  16. 16. BOARD-LIKE QUESTION ANSWER Which of the following is the most appropriate treatment for this patient's diabetes while hospitalized? A. Basal and prandial insulin B. Glipizide C. Metformin D. Sliding-scale insulin Educational Objective: Manage diabetes in a hospitalized patient Key Point: - For non-critically ill hospitalized patients with diabetes mellitus and hyperglycemia, a weight-based treatment plan that includes basal and prandial insulin is recommended.
  17. 17. REFERENCES  Effects of intensive glucose lowering in Type 2 Diabetes (2008). New England Journal of Medicine, 358:2545.-2559. doi 10.1056/NEJMoa0802743  Hunt, D, et al. The Evidence. Revised ed. Selected Nights; 2004: 77.

Hinweis der Redaktion

  • Item 38 from endocrinology
  • Item 38 from endocrinology

×